Expanding from
Single Cancer Tests
to a Multi-Cancer Screen

IONIQ Development Status

ProLung (Lung Cancer Test) - Multiple Studies Completed
Breast Cancer Test - In Feasibility Testing
Multi-Cancer Screen

The ProLung Test

Lung cancer is the leading cause of cancer-related deaths worldwide

Shifting the diagnosis to the earliest stages of the disease can improve 5 year survivability from 17% to 80%

  • The ProLung Test is designed to empower physicians to accelerate their diagnosis
  • The ProLung Test has undergone 7 clinical trials
  • Over 1,000 subjects tested as part of our clinical trials
  • Designated Breakthrough Device by US FDA for its life-enhancing potential
  • Not available for sale in the USA

IONIQ Breast Test

Breast cancer is the leading cause of cancer in women

5 year survival for breast cancer is 5x higher in the earliest stage of the disease

  • Bench work started 2019
  • Feasibility study started January 2020 (ongoing)
  • Our preliminary data shows promise
  • Clinical validation trial to follow completion of feasibility study
  • Not available for sale in the USA

We aim to be the first FDA cleared
Multi-Cancer Screen

Screening can save lives and money by detecting cancer at its earliest most treatable stages

Our lung cancer and breast cancer tests are foundational on our quest to developing a Multi-Cancer Screen.

We are well positioned to develop a multi-cancer screen by leveraging our lung test, breast test, proprietary technology, substantial EIA database, and our deep clinical experience.

Not available for sale in the USA.